Kathleen M. Dungan MD, MPH
Professor of Medicine and Interim Director, Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus, OhioDr. Kathleen Dungan is Professor of Medicine in the Division of Endocrinology, Diabetes and Metabolism at The Ohio State University where she serves as Interim Director for the Division.
Dr. Dungan earned her medical degree from The Ohio State University and completed her residency in internal medicine and fellowship in endocrinology at the University of North Carolina. She then completed her master’s in public health at The Ohio State University. She regularly appears on the "Best Doctors" list. She has served as primary investigator for NIH and other externally sponsored clinical research in glycemic management of hospitalized patients. She has served as lead investigator, steering committee, or national lead for a number of multicenter clinical trials involving diabetes therapeutics and monitoring. She serves as Associate Editor for Endotext and has served on planning committees for the American Diabetes Association Scientific Sessions and the Endocrine Society Clinical Endocrine Update, as well as other editorial board and continuing education planning activities. She has served on advisory panels, clinical trial steering committees, and has published widely on inpatient and outpatient diabetes therapeutics and monitoring.
Disclosures
- Consultant: Eli Lilly, Dexcom, Insulet
- Institutional research funding: Dexcom; ViaCyte; Abbott; Insulet
- Honoraria: Academy for Continued Healthcare Learning; Med Learning Group
- Royalties: UpToDate
Recent Contributions to PracticeUpdate:
- 2023 Top Story in Diabetes: Triple Receptor Hormone Agonists for the Treatment of Type 2 Diabetes and Obesity
- 2022 Top Story in Diabetes: Comparative Effectiveness of Common Type 2 Diabetes Therapies—Long-Awaited Results From the GRADE Study
- Glucose Metabolism After Pancreaticoduodenectomy: A 3-Year Observation
- ADA 2022: Recommendations From Dr. Kathleen Dungan
- 2021 Top Story in Diabetes: “Twincretin” Maximizes Glucose Control and Weight Loss
- ADA 2021: Recommendations From Dr. Kathleen Dungan
- Once-Weekly Semaglutide in Overweight or Obese Adults
- Efficacy and Safety of Three Dulaglutide Doses in Type 2 DM
- 2020 Top Stories in Diabetes: COVID-19 Prompts Transformations in Diabetes Healthcare Delivery
- Semaglutide Reduces CV Events in Type 2 Diabetes Across the Spectrum of CV Risk